A challenge to the data miners

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 12, 2004, Pages 881-884

  Lilienfeld, David E ^a  

^a InterMune Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ALGORITHM; ARTICLE; DATA BASE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; INFORMATION PROCESSING; METHODOLOGY; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; TECHNIQUE; TELEPHONE; UNITED STATES; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 10844281077     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1045     Document Type: Article

References (29)

1. Hauben M. A brief primer on automated signal detection. Ann Pharmacother 2003; 37: 1117-1123.
2. Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Safe 2003; 12: 517-521.
3. Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf 2002; 26 393-397.
4. Bate A, Lindquist M, Orre R, Edwards IR, Meyboom RH. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur J Clin Pharmacol 2002; 58: 438-490.
5. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-321.
6. Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol on-line 2003.
7. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system (with discussion). Am Stat 1999; 53: 177-190.
8. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25: 381-392.
9. Edwards IR, Lindquist Bate A, Orre R. Data mining. In Pharmacovigilance, Mann RD, Andrews EB (eds). John Wiley and Sons: Chichester, 2002.
10. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RHB. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO database. Drug Saf 2000; 23: 533-542.
11. Lilienfeld D, Nicholas S, Macneil D, Kurjatkin O, Gelardin T. Violation of homogeneity: a methodologic issue in the use of data mining tools. Drug Saf 2003; 26: 363-364.
12. Seligman P. Implementation of data mining at FDA/CDER. 5 November 2003. http://www.fda.gov/cder/Offices/OPaSS/ PhRMA-Data%20Mining%20November%2020031/ [accessed on 27 January 2004].
13. Item. 'FDA moves ahead with adverse event data-mining; "white paper" out soon.' 'The Pink Sheet' 66:4, January 26, 2004, p. 11.
14. Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In Pharmacoepidemiology (3rd edn), Strom B (ed.). J Wiley and Sons: New York, 2001.
15. Maeder T. Adverse Reactions. W Morrow: New York, 1994.
16. Council on Drugs. Development and purpose of the registry on blood dyscrasias. JAMA 1959; 170: 1925-1926.
17. Smith PG. Statistical analysis of cancer clusters. In Cancer Epidemiology (1st edn), Schottenfeld D, Fraumeni JF (eds). WB Saunders: Philadelphia, 1982.
18. Wartenberg D, Greenberg M. Detecting disease clusters: the importance of statistical error. Am J Epidemiol 1990; 132 Suppl. 1): S156-S166.
19. Beral V. Childhood leukemia near nuclear plants in the United Kingdom: the evolution of a systematic approach to studying rare disease in small geographic areas. Am J Epidemiol 1990; 132(Suppl. 1): S63-S68.
20. American Journal of Epidemiology: clustering of health events. Am J Epidemiol 1990; 132(Suppl. 1): S1-S2.
21. Rothman KJ. A sobering start for the Cluster Busters' Conference. Am J Epidemiol 1990; 132(Suppl. 1): S6-S13.
22. Caldwell GG. Twenty-two years of cancer cluster investigations at the Centers for Disease Control. Am J Epidemiol 1990; 132(Suppl. 1): S43-S47.
23. Cartwright RA. Cluster investigations: are they worth it? Med J Aust 1999; 171(4): 172.
24. O'Neill RT, Szarfman A. Discussion. Am Stat 1999; 53 190-196.
25. Niu MT, Erwin DE, Braun MM. Data mining in the US vaccine adverse event reporting system (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 2001; 19: 4627-4634.
26. O'Neill RT, Szarfman A. Some FDA perspectives on data mining for pediatric safety assessment. Curr Ther Res Clin Exp 2001; 62 650-663.
27. Stephens MDB. Introduction. In Detection of New Adverse Drug Reactions (4th edn), Stephens MDB, Talbot JCC, Routledge PA (eds). MacMillan: London, 1999.
28. Scott HD, Rosenbaum SE, Waters WJ, et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J 1987; 70: 311-316.
29. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Martin Arias LH. Under-reporting of adverse drug reactions. Eur J Clin Pharmacol 1998; 54: 483-488.